Compare · MDLN vs XENT
MDLN vs XENT
Side-by-side comparison of Medline Inc. (MDLN) and Intersect ENT Inc. (XENT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and XENT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.15B, about 48.5x XENT ($911.2M).
- MDLN has hit the wire 20 times in the past 4 weeks while XENT has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 5 for XENT).
- Company
- Medline Inc.
- Intersect ENT Inc.
- Price
- $33.03-1.68%
- $28.25+0.02%
- Market cap
- $44.15B
- $911.2M
- 1M return
- -21.32%
- -
- 1Y return
- -18.88%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2014
- News (4w)
- 20
- 0
- Recent ratings
- 25
- 5
Intersect ENT Inc.
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
Latest XENT
- FDA Approval for SINUVA issued to INTERSECT ENT INC
- SEC Form POSASR filed by Intersect ENT Inc.
- SEC Form RW WD filed by Intersect ENT Inc.
- Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer
- SEC Form 15-12B filed by Intersect ENT Inc.
- SEC Form S-8 POS filed by Intersect ENT Inc.
- SEC Form EFFECT filed by Intersect ENT Inc.
- SEC Form 4 filed by Hattangadi Neil A
- SEC Form 4: Meier Richard A closing all direct ownership in the company
- SEC Form 4: Fernandez Reyna M closing all direct ownership in the company